Table 1 Characteristics of included ICU patients with SARS-CoV-2 infection according to 60-day outcome
Characteristics | Total N = 101 | Survivors N = 82 | Non-survivors N = 19 | P value |
|---|---|---|---|---|
Men (N, %) | 82 (82%) | 68 (83%) | 14 (74%) | 0.35 |
Age (years) | 59 ± 11 | 57 ± 10 | 63 ± 11 | 0.07 |
SOFA# score | 4 [3–7] | 4 [3–6] | 6 [4–8] | 0.005 |
SAPS II | 37 [31–45] | 37 [31–44] | 41 [33–48] | 0.45 |
Body mass index (kg/m2) | ||||
 < 30 | 63 (63%) | 53 (65%) | 10 (52%) |  |
 > 30 | 38 (38%) | 30 (37%) | 8 (42%) | 0.65 |
Comorbidity (N, %) | ||||
 Hypertension | 51 (51%) | 44 (54%) | 7 (36%) | 0.18 |
 Diabetes mellitus | 29 (29%) | 23 (28%) | 6 (34%) | 0.76 |
 Cardiovascular disease | 12 (12%) | 10 (12%) | 2 (11%) | 0.84 |
 Chronic respiratory disease | 18 (18%) | 15 (18%) | 3 (16%) | 0.81 |
 Chronic kidney disease | 14 (14%) | 11 (13%) | 3 (16%) | 0.78 |
 Cirrhosis | 2 (2%) | 2 (2%) | 0 | 0.49 |
 Previous cancer | 2 (2%) | 2 (2%) | 0 | 0.49 |
 Haematological malignancy | 6 (6%) | 5 (6%) | 1 (5%) | 0.89 |
Treatment (N, %) | ||||
 Glucocorticoids | 19 (19%) | 16 (19%) | 3 (16%) | 0.71 |
 ACE inhibitors | 28 (28%) | 22 (25%) | 6 (31%) | 0.67 |
Organ support therapy at day 0 (N, %) | ||||
 Sedative drugs | 71 (71%) | 55 (67%) | 16 (84%) | 0.14 |
 Neuromuscular blockers | 57 (57%) | 44 (54%) | 13 (68%) | 0.24 |
 Mechanical ventilation | 83 (83%) | 67 (82%) | 16 (84%) | 0.79 |
 Prone positioning | 53 (53%) | 42 (51%) | 9 (47%) | 0.76 |
 Haemodialysis | 11 (11%) | 10 (12%) | 1 (5%) | 0.38 |
Norepinephrine | ||||
 N (%) | 33 (33%) | 24 (29%) | 9 (47%) | 0.13 |
 Dosage (mg/h) | 0 [0–0.22] | 0 [0–0.1] | 0.1 [0–0.87] | 0.07 |
 Co-infections at day 3 (N, %) | 37 (37%) | 30 (36%) | 7 (37%) | 0.98 |